US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Type 2 Diabetes Mellitus · Irritable Bowel Syndrome · LXRX
LEXICON PHARMACEUTICALS
LEXICON PHARMACEUTICALS, INC.
LEXICON PHARMACEUTICALS drug portfolio — 16 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
8800 Technology Forest, The Woodlands, TX 77381, US HQ
1995 Founded
282 Employees
Public company Type
LXRX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 8800 Technology Forest, The Woodlands, TX 77381, US
- Founded
- 1995
- Employees
- 282
- Programs
- 0
- Drugs
- 16
- Patents
- 8
LEXICON PHARMACEUTICALS pipeline
Portfolio lens on 16 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
LEXICON PHARMACEUTICALS drug portfolio — 16 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Dopamine receptors; D2 & D3.
- Target
- Dopamine receptors; D2 & D3
- Mechanism
- Serotonin (5-HT) receptor antagonist
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
Development asset linked to LEXICON PHARMACEUTICALS in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Molecular target: Sodium/potassium-transporting ATPase.
- Target
- Sodium/potassium-transporting ATPase
- Mechanism
- Sodium/potassium-transporting ATPase inhibitor
-
Development asset linked to LEXICON PHARMACEUTICALS in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Potassium-transporting ATPase.
- Target
- Potassium-transporting ATPase
- Mechanism
- Potassium-transporting ATPase inhibitor
-
Development asset linked to LEXICON PHARMACEUTICALS in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
sotagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 1.
- Target
- Sodium/glucose cotransporter 1
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
Development asset linked to LEXICON PHARMACEUTICALS in public FDA and regional records. Mechanism: HERG blocker.
- Mechanism
- HERG blocker
-
telotristat ethyl
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in LEXICON PHARMACEUTICALS's portfolio. Molecular target: Tryptophan 5-hydroxylase.
- Target
- Tryptophan 5-hydroxylase
- Mechanism
- Tryptophan 5-hydroxylase inhibitor
-
US regulatory status: approved. Molecular target: Tryptophan 5-hydroxylase.
- Target
- Tryptophan 5-hydroxylase
- Mechanism
- Tryptophan 5-hydroxylase inhibitor